517 related articles for article (PubMed ID: 16410038)
1. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
2. Deactivation of P-glycoprotein by a novel compound, oxalyl bis (N-phenyl) hydroxamic acid.
Choudhuri SK
Neoplasma; 2002; 49(4):272-7. PubMed ID: 12382028
[TBL] [Abstract][Full Text] [Related]
3. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
Ganguly A; Basu S; Banerjee K; Chakraborty P; Sarkar A; Chatterjee M; Chaudhuri SK
Mol Biosyst; 2011 May; 7(5):1701-12. PubMed ID: 21409205
[TBL] [Abstract][Full Text] [Related]
4. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
5. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
6. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
7. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
9. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
10. A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer.
Ghosh RD; Banerjee K; Das S; Ganguly A; Chakraborty P; Sarkar A; Chatterjee M; Choudhuri SK
Eur J Pharm Sci; 2013 Jul; 49(4):737-47. PubMed ID: 23665413
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
12. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
14. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
15. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
16. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
[TBL] [Abstract][Full Text] [Related]
17. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Abulrob AN; Mason M; Bryce R; Gumbleton M
J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
19. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
[TBL] [Abstract][Full Text] [Related]
20. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
